Investigation of antimicrobial susceptibility, class I, II, and III integrons among clinical isolates of Pseudomonas aeruginosa from hospitalized burn patients in Southern Iran

Gene type	Primer/Sequence (5′ 3′)	Product Size (bp)	References
IntI1	F:GGTCAAGGATCTGGATTTCG	483	[38]
IntI1	R:ACATGCGTGTAAATCATCGTC	483	[38]
IntI2	F:CACGGATATGCGACAAAAAGGT	789	[38]
IntI2	R:GTAGCAAACGAGTGACGAAATG	789	[38]
IntI3	F:AGTGGGTGGCGAATGAGTG	580	[38]
IntI3	R:TGTTCTTGTATCGGCAGGTG	580	[38]

Frequency of antibiotics resistance pattern in intI1-positive and -negative among P. aeruginosa isolates

Antibiotic		intI1- positive n = 36 No. (%)	intI1- negative n = 34 No. (%)	P-value
Piperacillin/tazobactam	Resistant	34 (94.4)	31 (91.2)	0.59
Piperacillin/tazobactam	Susceptible	2 (5.6)	3 (8.8)	0.59
Ceftazidime	Resistant	29 (80.6)	32 (94.1)	0.09
Ceftazidime	Susceptible	7 (19.4)	2 (5.9)	0.09
Imipenem	Resistant	35 (97.2)	31 (91.2)	0.27
Imipenem	Susceptible	1 (2.8)	3 (8.8)	0.27
Ciprofloxacin	Resistant	30 (83.3)	27 (79.4)	0.67
Ciprofloxacin	Susceptible	6 (16.7)	7 (20.6)	0.67
Gentamicin	Resistant	35 (97.2)	33 (97)	0.96
Gentamicin	Susceptible	1 (2.8)	1 (3)	0.96

Frequency of antibiotic resistance pattern in intI2-positive and negative among P. aeruginosa isolates

Antibiotics		intI2 - positive n = 21 No. (%)	intI2 - negative n = 49 No. (%)	P-value
Piperacillin/tazobactam	Resistant	19 (90.5)	46(93.9)	0.61
Piperacillin/tazobactam	Susceptible	2 (9.5)	3 (6.1)	0.61
Ceftazidime	Resistant	20 (95.2)	41 (83.7)	0.18
Ceftazidime	Susceptible	1 (4.8)	8 (16.3)	0.18
Imipenem	Resistant	19 (90.5)	47 (95.9)	0.36
Imipenem	Susceptible	2 (9.5)	2 (4.1)	0.36
Ciprofloxacin	Resistant	15 (71.4)	42 (85.7)	0.15
Ciprofloxacin	Susceptible	6 (28.6)	7 (14.3)	0.15
Gentamicin	Resistant	20 (95.2)	47 (95.9)	0.89
Gentamicin	Susceptible	1 (4.8)	2 (4.1)	0.89

Language: English

Page range: 170 - 175

Submitted on: Apr 10, 2022

Accepted on: Mar 31, 2023

Published on: Mar 14, 2024

Published by: Hirszfeld Institute of Immunology and Experimental Therapy

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

Related subjects:

© 2024 Rezvan Mirzaei, Fereshte Ghandehari, Nazanin Delroshan, Laleh Hoveida, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.